Central anticholinergic syndrome in anesthetic practice.
Anticholinergic agents may lead to a syndrome described by Longo as the Central Anticholinergic Syndrome (CAS). Patients with this syndrome exhibit one or more of the following: though impairement, disturbance of recent memory, hallucinations, ataxia, excitement, drowsiness of coma. We have reviewed our use of anticholinergics and tried to correlate it with the occurrence of the above symptomatology and have treated 200 cases in which the CAS was diagnosed with physostigmine salicylate (0.04 mg/kg). We also successfully treated 2 cases of apparently central anticholinergic hyperpyrexia in the same way. We would suggest that physostigmine be included in the armamentarium of every anesthetist to combat anticholinergic poisoning by the wide range of presently used anticholinergic drugs. (Act anaesth. belg., 1976, 27, 45-60).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000758:Anesthesia; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced / Q000503:physiopathology; D010275:Parasympathetic Nervous System; D010276:Parasympatholytics / Q000009:adverse effects*; D010830:Physostigmine / Q000627:therapeutic use; D013569:Synapses / Q000187:drug effects*
D010276:Parasympatholytics; D010830:Physostigmine